LFCR

+ Watchlist + Portfolio

Lifecore Biomedical, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $4.46
52-Week Range: $3.63 – $8.98
Market Cap: $171.10M
P/E (TTM): —
EPS (TTM): -1.27
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: 2.66
Return on Equity: —
Return on Assets: —
Gross Margin: 31.37%
Operating Margin: 7.51%
Profit Margin: -23.78%
Current Ratio: 3.49
Debt/Equity: 9.72
Total Debt: $156.38M
Free Cash Flow: —
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $361.17M

LFCR Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$111.27M	$103.27M	$128.26M	$128.87M
Cost of Revenue	$72.20M	$75.28M	$86.41M	$88.57M
Gross Profit	$39.07M	$27.98M	$41.85M	$40.30M
Research & Development	$7.84M	$8.74M	$8.57M	$8.26M
Selling, General & Admin	$34.66M	$38.97M	$40.46M	$44.05M
Operating Expenses	$42.50M	$47.70M	$49.04M	$52.30M
Operating Income	-$3.43M	-$19.72M	-$7.19M	-$12.01M
EBITDA	$12.84M	-$33.17M	$35.62M	-$8.48M
Pretax Income	-$20.69M	-$63.93M	$9.51M	-$38.67M
Income Tax	-$5.21M	$308.00K	$183.00K	$43.00K
Net Income	-$116.72M	-$99.56M	$12.01M	-$38.72M
Diluted EPS	-3.30	-3.41	0.32	-1.27
Diluted Shares	29.51M	29.97M	36.66M	34.82M

LFCR Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$19.09M	$8.46M	$8.27M	$17.47M
Receivables	$29.02M	$31.15M	$43.67M	$33.82M
Inventory	$40.84M	$39.98M	$32.29M	$29.09M
Current Assets	$93.88M	$81.03M	$85.68M	$82.29M
Total Assets	$253.54M	$253.96M	$239.34M	$232.18M
Current Liabilities	$39.29M	$38.87M	$30.18M	$23.57M
Long-Term Debt	$101.06M	$123.72M	$127.00M	$135.59M
Total Debt	$112.62M	$128.63M	$130.82M	$142.61M
Total Liabilities	$257.77M	$242.65M	$238.01M	$246.38M
Retained Earnings	-$178.54M	-$166.52M	-$205.24M	-$223.20M
Shareholders' Equity	-$4.23M	$11.31M	$1.34M	-$14.20M
Working Capital	$54.59M	$42.16M	$55.50M	$58.72M
Net Debt	$82.55M	$116.21M	$122.17M	$118.89M

LFCR Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$22.59M	-$17.44M	$257.00K	-$206.00K
Capital Expenditure	-$29.94M	-$21.48M	-$18.39M	-$13.41M
Free Cash Flow	-$52.53M	-$38.92M	-$18.14M	-$13.62M
Depreciation & Amortisation	$18.06M	$13.18M	$7.95M	$8.03M
Stock-Based Compensation	$2.61M	$3.61M	$6.20M	$10.16M
Investing Cash Flow	$79.96M	-$4.81M	-$18.39M	-$6.42M
Financing Cash Flow	-$57.02M	$39.70M	$7.51M	$6.42M
Net Change in Cash	$348.00K	$17.45M	-$10.63M	-$197.00K

LFCR Income statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Revenue	$32.56M	$35.15M	$36.44M	$31.11M	$23.19M
Cost of Revenue	$21.48M	$25.31M	$22.46M	$23.32M	$18.73M
Gross Profit	$11.08M	$9.85M	$13.98M	$7.79M	$4.46M
Research & Development	$1.92M	$2.04M	$2.10M	$1.96M	$1.22M
Selling, General & Admin	$11.12M	$9.98M	$8.98M	$8.89M	$7.92M
Operating Expenses	$13.04M	$12.02M	$11.08M	$10.86M	$9.13M
Operating Income	-$1.96M	-$2.18M	$2.90M	-$3.07M	-$4.67M
EBITDA	$981.00K	-$7.11M	$6.32M	-$1.29M	-$5.28M
Pretax Income	-$6.53M	-$14.78M	-$1.11M	-$9.66M	-$14.94M
Income Tax	$43.00K	-$8.00K	$33.00K	$333.00K	$43.00K
Net Income	-$6.57M	-$14.77M	-$1.15M	-$9.99M	-$14.98M
Diluted EPS	-0.25	-0.47	-0.06	-0.29	-0.43
Diluted Shares	34.36M	37.02M	37.01M	37.40M	37.48M

LFCR Balance Sheet statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Cash & Equivalents	$9.46M	$5.42M	$8.27M	$18.86M	$20.80M
Receivables	$30.30M	$41.65M	$43.67M	$29.13M	$26.89M
Inventory	$39.21M	$34.60M	$32.29M	$33.80M	$28.16M
Current Assets	$81.86M	$84.21M	$85.68M	$83.93M	$77.64M
Total Assets	$255.39M	$237.69M	$239.34M	$235.20M	$225.50M
Current Liabilities	$35.29M	$31.12M	$30.18M	$29.96M	$20.50M
Long-Term Debt	$119.03M	$124.01M	$127.00M	$135.00M	$142.14M
Total Debt	$131.34M	$130.34M	$130.82M	$135.95M	$148.74M
Total Liabilities	$239.94M	$235.46M	$238.01M	$245.74M	$253.94M
Retained Earnings	-$191.46M	-$204.09M	-$205.24M	-$218.09M	-$238.18M
Shareholders' Equity	$15.45M	$2.23M	$1.34M	-$10.54M	-$28.44M
Working Capital	$46.57M	$53.09M	$55.50M	$53.97M	$57.14M
Net Debt	$110.35M	$119.52M	$122.17M	$117.09M	$122.11M

LFCR Cash Flow statement, quarterly periods, in USD
USD	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Operating Cash Flow	-$6.14M	$1.20M	$5.35M	$1.76M	$4.70M
Capital Expenditure	-$2.44M	-$5.46M	-$2.10M	-$1.74M	-$1.12M
Free Cash Flow	-$8.58M	-$4.26M	$3.25M	$25.00K	$3.58M
Depreciation & Amortisation	$2.04M	$2.08M	$1.91M	$1.98M	$2.31M
Stock-Based Compensation	$3.37M	$2.55M	$1.81M	$2.39M	$1.70M
Investing Cash Flow	-$2.44M	$1.54M	-$2.10M	-$1.74M	-$1.12M
Financing Cash Flow	$12.52M	-$6.78M	-$402.00K	-$1.39M	-$256.00K
Net Change in Cash	$3.94M	-$4.04M	$2.85M	-$1.36M	$3.33M

Market Snapshot

About

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) specializing in complex sterile injectable pharmaceutical products. The company provides services including formulation development, aseptic fill-finish manufacturing, and commercial production for pharmaceutical and biotechnology companies. Lifecore also produces sodium hyaluronate, a biomaterial used in ophthalmic, orthopedic, and other medical applications.